Status:
UNKNOWN
Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum
Lead Sponsor:
National Jewish Health
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Atopic Dermatitis With a History of Eczema Herpeticum
Atopic Dermatitis Without a History of Eczema Herpeticum
Eligibility:
All Genders
16-65 years
Brief Summary
This study investigates whether blood monocytes' surface bound- immunoglobulin E affects the innate immune responses against herpes simplex viruses in atopic dermatitis patients with eczema herpeticum...
Detailed Description
Some of atopic dermatitis patients (AD) have severe herpes simplex viral (HSV) infections, which could cause erosive skin lesions all over the body. This condition is termed as eczema herpeticum (ADEH...
Eligibility Criteria
Inclusion
- Age 16-65 years old, age, sex and race match among non-atopic, ADEH- and ADEH+.
- Participant and/or parent guardian must be able to understand and provide informed consent, and fits in one of the following conditions:
- A history of AD with a history of eczema herpeticum, ADEH+, as diagnosed using the Atopic Dermatitis Research Network Standard Diagnostic Criteria.
- A history of AD without a history of eczema herpeticum, ADEH-, as diagnosed using Atopic Dermatitis Research Network Standard Diagnostic Criteria, and no first degree relatives with a history of EH.
- Non-atopic as diagnosed using Atopic Dermatitis Research Network Standard Diagnostic Criteria.
Exclusion
- Inability or unwillingness of a participant to give written informed consent or comply with study protocol
- Known or suspected immunosuppression
- Severe concomitant illness(es)
- Women of childbearing potential not using the contraception method(s) specified in this study (specify), as well as women who are breastfeeding
- Known sensitivity to study drug(s) or class of study drug(s)
- Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required)
- Use of any other investigational agent in the last 30 days
Key Trial Info
Start Date :
January 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2021
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04060550
Start Date
January 9 2020
End Date
July 31 2021
Last Update
March 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Jewish Health
Denver, Colorado, United States, 80206